As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
Social media emerges as the primary channel for health-related scams, while influencer endorsements and AI-generated content amplify risks for consumers
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows
As per union government, growing public participation reflects rising awareness and collective commitment towards advancing organ and tissue donation
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
